Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Runjian Signs US$200 Million Overseas AI Inference Contract, Keeping Computing Resources in China

Runjian（润建股份）disclosed on October 18 that its wholly owned subsidiary Wuxiang Yungu（五象云谷）had signed a one-year AI token services contract with an unidentified overseas company. The agreement includes a US$200 million minimum annual purchase commitment, equivalent to approximately CNY 1.338 billion, with computing resources hosted in China and services accessed remotely through an API.

China Proposes Export Restrictions on 23 AI Technologies, Keeps API Services Outside Large-Model Transfer Rules

China’s Ministry of Commerce and Ministry of Science and Technology published proposed additions to the country’s technology-export catalogue on October 16, covering 23 AI technologies. Accompanying guidance distinguishes transfers of restricted technology from services such as overseas API access, while a temporary registration requirement has already taken effect.

Semight Instruments Plans Hong Kong Listing to Broaden Offshore Financing Options

Semight Instruments（联讯仪器）, a Suzhou-based supplier of test instruments and equipment, has secured board approval to pursue an H-share listing on the Hong Kong Stock Exchange’s Main Board. The proposal advances the company’s plans to broaden offshore financing access, although shareholder approval and regulatory procedures remain outstanding.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.